世界のライム病診断市場2021-2031:産業分析、規模、シェア、成長、動向、予測

• 英文タイトル:Lyme Disease Diagnostics Market (Diagnostic Test: Serological Test, Polymerase Chain Reaction [PCR] Testing, Immunofluorescence [IFA], Lymphocyte Transformation Test, Urine Antigen Testing, and Others; Sample: Blood, Cerebrospinal Fluid [CSF], Joint Fluid, and Urine; and End User: Hospitals, Clinical Laboratories, Physician Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Lyme Disease Diagnostics Market (Diagnostic Test: Serological Test, Polymerase Chain Reaction [PCR] Testing, Immunofluorescence [IFA], Lymphocyte Transformation Test, Urine Antigen Testing, and Others; Sample: Blood, Cerebrospinal Fluid [CSF], Joint Fluid, and Urine; and End User: Hospitals, Clinical Laboratories, Physician Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031「世界のライム病診断市場2021-2031:産業分析、規模、シェア、成長、動向、予測」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2107A025
• 出版社/出版日:Transparency Market Research / 2021年6月30日
• レポート形態:英文、PDF、180ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥637,450 (USD5,795)▷ お問い合わせ
  Site Licence¥967,450 (USD8,795)▷ お問い合わせ
  Enterprise Licence¥1,297,450 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Transparency Market Research社の本調査レポートでは、ライム病診断の世界市場を広く調査し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、診断検査別(血清学的検査、ポリメラーゼ連鎖反応[PCR]検査、免疫蛍光[IFA]、リンパ球形質転換検査、尿抗原検査)分析、試料別分析、エンドユーザー別分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況などの項目を掲載しています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・市場見通し
・ライム病診断の世界市場規模:診断検査別(血清学的検査、ポリメラーゼ連鎖反応[PCR]検査、免疫蛍光[IFA]、リンパ球形質転換検査、尿抗原検査)
・ライム病診断の世界市場規模:試料別
・ライム病診断の世界市場規模:エンドユーザー別
・ライム病診断の世界市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)
・競争状況

Lyme Disease Diagnostics Market – Scope of Report

TMR’s report on the global Lyme disease diagnostic market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the global Lyme disease diagnostic market for the period of 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Lyme disease diagnostic market from 2021 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Lyme disease diagnostic market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the Lyme disease diagnostic market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global Lyme disease diagnostic market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Lyme disease diagnostic market.

The report delves into the competitive landscape of the global Lyme disease diagnostic market. Key players operating in the global Lyme disease diagnostic market are identified and each one of these is profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Lyme disease diagnostic market profiled in this report.

Key Questions Answered in Lyme Disease Diagnostics Market Report
What is the sales/revenue generated by Lyme disease diagnostics across all regions during the forecast period?
What are the opportunities in the global Lyme disease diagnostic market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which diagnostic test segment is expected to generate the highest revenue globally in 2031? Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Lyme Disease Diagnostics Market – Research Objectives and Research Approach
The comprehensive report on the global Lyme disease diagnostic market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller one. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Lyme disease diagnostic market in terms of diagnostic test, sample, end user, and region. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2031 has also been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Lyme disease diagnostic market.

レポート目次

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.4. Global Lyme Disease Diagnostics Market Forecast
4.5. Global Lyme Disease Diagnostics Market Outlook
5. Market Outlook
5.1. Lyme Disease Epidemiology
5.2. Regulations Related to Lyme Disease
5.3. COVID-19 Pandemic Impact on Lyme Disease Diagnostics Industry
5.4. Key Industry Development
6. Global Lyme Disease Diagnostics Market Analysis, by Diagnostic Test
6.1. Introduction
6.2. Global Lyme Disease Diagnostics Market Value Share Analysis, by Diagnostic Test
6.3. Global Lyme Disease Diagnostics Market Forecast, by Diagnostic Test
6.3.1. Serological Test
6.3.1.1. ELISA
6.3.1.2. Western Blot
6.3.2. Polymerase Chain Reaction (PCR) Testing
6.3.3. Immunofluorescence (IFA)
6.3.4. lymphocyte Transformation Test
6.3.5. Urine Antigen Testing
6.3.6. Others
6.4. Global Lyme Disease Diagnostics Market Analysis, by Diagnostic Test
6.5. Global Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test
7. Global Lyme Disease Diagnostics Market Analysis, by Sample
7.1. Introduction
7.2. Global Lyme Disease Diagnostics Market Value Share Analysis, by Sample
7.3. Global Lyme Disease Diagnostics Market Forecast, by Sample
7.3.1. Blood
7.3.2. Cerebrospinal Fluid (CSF)
7.3.3. Joint Fluid
7.3.4. Urine
7.4. Global Lyme Disease Diagnostics Market Analysis, by Sample
7.5. Global Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample
8. Global Lyme Disease Diagnostics Market Analysis, by End-user
8.1. Introduction
8.2. Global Lyme Disease Diagnostics Market Value Share Analysis, by End-user
8.3. Global Lyme Disease Diagnostics Market Forecast, by End-user
8.3.1. Hospitals
8.3.2. Clinical Laboratories
8.3.3. Physician Clinics
8.3.4. Others
8.4. Global Lyme Disease Diagnostics Market Analysis, by End-user
8.5. Global Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user
9. Global Lyme Disease Diagnostics Market Analysis, by Region
9.1. Global Lyme Disease Diagnostics Market Scenario, by Region/Country
9.2. Global Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Region
9.3. Global Lyme Disease Diagnostics Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
10. North America Lyme Disease Diagnostics Market Analysis
10.1. North America Lyme Disease Diagnostics Market Overview
10.2. North America Lyme Disease Diagnostics Market Value Share Analysis, Diagnostic Test
10.3. North America Lyme Disease Diagnostics Forecast, by Diagnostic Test
10.3.1. Serological Test
10.3.1.1. ELISA
10.3.1.2. Western Blot
10.3.2. Polymerase Chain Reaction (PCR) Testing
10.3.3. Immunofluorescence (IFA)
10.3.4. lymphocyte Transformation Test
10.3.5. Urine Antigen Testing
10.3.6. Others
10.4. North America Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test
10.5. North America Lyme Disease Diagnostics Market Analysis, by Sample
10.6. North America Lyme Disease Diagnostics Market Forecast, by Sample
10.6.1. Blood
10.6.2. Cerebrospinal Fluid (CSF)
10.6.3. Joint Fluid
10.6.4. Urine
10.6.5. Others
10.7. North America Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample
10.8. North America Lyme Disease Diagnostics Market Analysis, by End-user
10.9. North America Lyme Disease Diagnostics Market Forecast, by End-user
10.9.1. Hospitals
10.9.2. Clinical Laboratories
10.9.3. Physician Clinics
10.9.4. Others
10.10. North America Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user
10.11. North America Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Country
10.12. North America Lyme Disease Diagnostics Market Forecast, by Country
10.12.1. U.S.
10.12.2. Canada
11. Europe Lyme Disease Diagnostics Market Analysis
11.1. Europe Lyme Disease Diagnostics Market Overview
11.2. Europe Lyme Disease Diagnostics Market Value Share Analysis, Diagnostic Test
11.3. Europe Lyme Disease Diagnostics Forecast, by Diagnostic Test
11.3.1. Serological Test
11.3.1.1. ELISA
11.3.1.2. Western Blot
11.3.2. Polymerase Chain Reaction (PCR) Testing
11.3.3. Immunofluorescence (IFA)
11.3.4. lymphocyte Transformation Test
11.3.5. Urine Antigen Testing
11.3.6. Others
11.4. Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test
11.5. Europe Lyme Disease Diagnostics Market Analysis, by Sample
11.6. Europe Lyme Disease Diagnostics Market Forecast, by Sample
11.6.1. Blood
11.6.2. Cerebrospinal Fluid (CSF)
11.6.3. Joint Fluid
11.6.4. Urine
11.7. Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample
11.8. Europe Lyme Disease Diagnostics Market Analysis, by End-user
11.9. Europe Lyme Disease Diagnostics Market Forecast, by End-user
11.9.1. Hospitals
11.9.2. Clinical Laboratories
11.9.3. Physician Clinics
11.9.4. Others
11.10. Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user
11.11. Europe Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.12. Europe Lyme Disease Diagnostics Market Forecast, by Country/Sub-region
11.12.1. Germany
11.12.2. France
11.12.3. U.K.
11.12.4. Italy
11.12.5. Spain
11.12.6. Rest of Europe
12. Asia Pacific Lyme Disease Diagnostics Market Analysis
12.1. Asia Pacific Lyme Disease Diagnostics Market Overview
12.2. Asia Pacific Lyme Disease Diagnostics Market Value Share Analysis, Diagnostic Test
12.3. Asia Pacific Lyme Disease Diagnostics Forecast, by Diagnostic Test
12.3.1. Serological Test
12.3.1.1. ELISA
12.3.1.2. Western Blot
12.3.2. Polymerase Chain Reaction (PCR) Testing
12.3.3. Immunofluorescence (IFA)
12.3.4. lymphocyte Transformation Test
12.3.5. Urine Antigen Testing
12.3.6. Others
12.4. Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test
12.5. Asia Pacific Lyme Disease Diagnostics Market Analysis, by Sample
12.6. Asia Pacific Lyme Disease Diagnostics Market Forecast, by Sample
12.6.1. Blood
12.6.2. Cerebrospinal Fluid (CSF)
12.6.3. Joint Fluid
12.6.4. Urine
12.7. Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample
12.8. Asia Pacific Lyme Disease Diagnostics Market Analysis, by End-user
12.9. Asia Pacific Lyme Disease Diagnostics Market Forecast, by End-user
12.9.1. Hospitals
12.9.2. Clinical Laboratories
12.9.3. Physician Clinics
12.9.4. Others
12.10. Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user
12.11. Asia Pacific Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.12. Asia Pacific Lyme Disease Diagnostics Market Forecast, by Country/Sub-region
12.12.1. Japan
12.12.2. China
12.12.3. India
12.12.4. Australia & New Zealand
12.12.5. Rest of Asia Pacific
13. Latin America Lyme Disease Diagnostics Market Analysis
13.1. Latin America Lyme Disease Diagnostics Market Overview
13.2. Latin America Lyme Disease Diagnostics Market Value Share Analysis, Diagnostic Test
13.3. Latin America Lyme Disease Diagnostics Forecast, by Diagnostic Test
13.3.1. Serological Test
13.3.1.1. Elisa
13.3.1.2. Western Blot
13.3.2. Polymerase Chain Reaction (PCR) Testing
13.3.3. Immunofluorescence (IFA)
13.3.4. lymphocyte Transformation Test
13.3.5. Urine Antigen Testing
13.3.6. Others
13.4. Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test
13.5. Latin America Lyme Disease Diagnostics Market Analysis, by Sample
13.6. Latin America Lyme Disease Diagnostics Market Forecast, by Sample
13.6.1. Blood
13.6.2. Cerebrospinal Fluid (CSF)
13.6.3. Joint Fluid
13.6.4. Urine
13.7. Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample
13.8. Latin America Lyme Disease Diagnostics Market Analysis, by End-user
13.9. Latin America Lyme Disease Diagnostics Market Forecast, by End-user
13.9.1. Hospitals
13.9.2. Clinical Laboratories
13.9.3. Physician Clinics
13.9.4. Others
13.10. Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user
13.11. Latin America Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.12. Latin America Lyme Disease Diagnostics Market Forecast, by Country/Sub-region
13.12.1. Brazil
13.12.2. Mexico
13.12.3. Rest of Latin America
14. Middle East & Africa Lyme Disease Diagnostics Market Analysis
14.1. Middle East & Africa Lyme Disease Diagnostics Market Overview
14.2. Middle East & Africa Lyme Disease Diagnostics Market Value Share Analysis, Diagnostic Test
14.3. Middle East & Africa Lyme Disease Diagnostics Forecast, by Diagnostic Test
14.3.1. Serological Test
14.3.1.1. ELISA
14.3.1.2. Western Blot
14.3.2. Polymerase Chain Reaction (PCR) Testing
14.3.3. Immunofluorescence (IFA)
14.3.4. lymphocyte Transformation Test
14.3.5. Urine Antigen Testing
14.3.6. Others
14.4. Middle East & Africa Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test
14.5. Middle East & Africa Lyme Disease Diagnostics Market Analysis, by Sample
14.6. Middle East & Africa Lyme Disease Diagnostics Market Forecast, by Sample
14.6.1. Blood
14.6.2. Cerebrospinal Fluid (CSF)
14.6.3. Joint Fluid
14.6.4. Urine
14.7. Middle East & Africa Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample
14.8. Middle East & Africa Lyme Disease Diagnostics Market Analysis, by End-user
14.9. Middle East & Africa Lyme Disease Diagnostics Market Forecast, by End-user
14.9.1. Hospitals
14.9.2. Clinical Laboratories
14.9.3. Physician Clinics
14.9.4. Others
14.10. Middle East & Africa Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user
14.11. Middle East & Africa Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.12. Middle East & Africa Lyme Disease Diagnostics Market Forecast, by Country/Sub-region
14.12.1. GCC Countries
14.12.2. South Africa
14.12.3. Rest of Middle East & Africa
15. Competition Landscape
15.1. Competition Matrix
15.2. Company Profiles
15.2.1. T2 Biosystems, Inc.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. QIAGEN
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. SWOT Analysis
15.2.2.4. Strategic Overview
15.2.3. DiaSorin S.p.A.
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. SWOT Analysis
15.2.3.4. Strategic Overview
15.2.4. Bio-Rad Laboratories
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. SWOT Analysis
15.2.4.4. Strategic Overview
15.2.5. Thermo Fisher Scientific, Inc.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Trinity Biotech plc
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. SWOT Analysis
15.2.6.4. Strategic Overview
15.2.7. IGeneX, Inc.
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. SWOT Analysis
15.2.7.4. Strategic Overview
15.2.8. Lyme Diagnostics Ltd.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. SWOT Analysis
15.2.8.4. Strategic Overview
15.2.9. PerkinElmer, Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. SWOT Analysis
15.2.9.4. Strategic Overview
15.2.10. Oxford Immunotec plc (Boulder Diagnostics)
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Product Portfolio
15.2.10.3. SWOT Analysis
15.2.10.4. Strategic Overview
15.2.11. Cenogenics Corporation
15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.11.2. Product Portfolio
15.2.11.3. SWOT Analysis
15.2.11.4. Strategic Overview
15.2.12. Quest Diagnostics
15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.12.2. Product Portfolio
15.2.12.3. SWOT Analysis
15.2.12.4. Strategic Overview
15.2.13. Ceres Nanosciences, Inc.
15.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.13.2. Product Portfolio
15.2.13.3. SWOT Analysis
15.2.13.4. Strategic Overview
15.2.14. Galaxy Diagnostics
15.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.14.2. Product Portfolio
15.2.14.3. SWOT Analysis
15.2.14.4. Strategic Overview

List of Tables

Table 01: Global Lyme Disease Diagnostics Market

Table 02: 2019A Total Revenue

Table 03: 2031F Total Revenue

Table 04: Executive Summary

Table 05: Market Overview

Table 06: Key Industry Events

Table 07: Impact of COVID-19 Pandemic

Table 08: Global Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Test, 2017–2031

Table 09: Global Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Serological Test, 2017–2031

Table 10: Global Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Sample, 2017–2031

Table 11: Global Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 12: Global Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Region , 2017–2031

Table 13: North America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Test, 2017–2031

Table 14: North America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Serological Test, 2017–2031

Table 15: North America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Sample, 2017–2031

Table 16: North America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 17: North America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 18: Europe Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Test, 2017–2031

Table 19: Europe Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Serological Test, 2018

Table 20: Europe Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Sample, 2017–2031

Table 21: Europe Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 22: Europe Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-segment, 2017–2031

Table 23: Asia Pacific Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Test, 2017–2031

Table 24: Asia Pacific Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Serological Test, 2017–2031

Table 25: Asia Pacific Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Sample, 2017–2031

Table 26: Asia Pacific Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 27: Asia Pacific Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-segment, 2017–2031

Table 28: Latin America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Test, 2017–2031

Table 29: Latin America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Serological Test, 2017–2031

Table 30: Latin America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Sample, 2017–2031

Table 31: Latin America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 32: Latin America Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 33: Middle East & Africa Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Test, 2017–2031

Table 34: Middle East & Africa Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Serological Test, 2017–2031

Table 35: Middle East & Africa Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Sample, 2017–2031

Table 36: Middle East & Africa Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 37: Middle East & Africa Lyme Disease Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-segment, 2017–2031

Table 38: T2 Biosystems, Inc.: Business Overview

Table 39: T2 Biosystems, Inc.: Strategic Overview

Table 40: QIAGEN.: Business Overview

Table 41: QIAGEN.: Strategic Overview

Table 42: DiaSorin S.p.A.: Business Overview

Table 43: DiaSorin S.p.A.: Strategic Overview

Table 44: Bio-Rad Laboratories: Business Overview

Table 45: Bio-Rad Laboratories: Strategic Overview

Table 46: Thermo Fisher Scientific, Inc.: Business Overview

Table 47: Thermo Fisher Scientific, Inc.: Strategic Overview

Table 48: Trinity Biotech plc: Business Overview

Table 49: Trinity Biotech plc: Strategic Overview

Table 50: Trinity Biotech plc: Business Overview

Table 51: Trinity Biotech plc: Strategic Overview

Table 52: IGeneX, Inc.: Business Overview

Table 53: IGeneX, Inc.: Strategic Overview

Table 54: Lyme Diagnostics Ltd.: Business Overview

Table 55: Lyme Diagnostics Ltd.: Strategic Overview

Table 56: PerkinElmer, Inc.: Business Overview

Table 57: PerkinElmer, Inc.: Strategic Overview

Table 58: Oxford Immunotec plc (Boulder Diagnostics): Business Overview

Table 59: Oxford Immunotec plc (Boulder Diagnostics): Strategic Overview

Table 60: Cenogenics Corporation: Business Overview

Table 61: Cenogenics Corporation: Strategic Overview

Table 62: Quest Diagnostics.: Business Overview

Table 63: Quest Diagnostics.: Strategic Overview

Table 64: Ceres Nanosciences, Inc.: Business Overview

Table 65: Ceres Nanosciences, Inc.: Strategic Overview

Table 66: Galaxy Diagnostics: Business Overview

Table 67: Galaxy Diagnostics: Strategic Overview


• 英文レポート名:Lyme Disease Diagnostics Market (Diagnostic Test: Serological Test, Polymerase Chain Reaction [PCR] Testing, Immunofluorescence [IFA], Lymphocyte Transformation Test, Urine Antigen Testing, and Others; Sample: Blood, Cerebrospinal Fluid [CSF], Joint Fluid, and Urine; and End User: Hospitals, Clinical Laboratories, Physician Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031
• 日本語訳:世界のライム病診断市場2021-2031:産業分析、規模、シェア、成長、動向、予測
• レポートコード:MRC2107A025お問い合わせ(見積依頼・ご注文・質問)